semaglutide heart problems cardiovascular outcomes align more closely with attained dose than achieved weight loss VisualAbstract: Semaglutide Improves Outcomes in

The jump from 1mg to 1.7mg (a 70% increase) typically produces more side effects than the jump from 0.25mg to 0.5mg (a 100% increase but from a much lower base)

Figure from van der Aart-van der Beek AB, Nat Rev Nephrol, 2020 The Study Methods This was an international, event-driven, double-blind, parallel-group, randomized, placebo-controlled trial conducted at 387 sites in 28 countries comparing semaglutide to placebo in patients with T2DM and CKD, both being treated with baseline standard of care

Just select your region at the top, and it will automatically populate the page with that regions formularies

In the STEP-1 trial studying Wegovy at 2.4 mg weekly, about 44% of participants reported nausea at some point during treatment

Theyre the only ones who know your specific case and can make the best decision for you

Because tirzepatide activates two receptors rather than one, the biological response to reduced exposure may not mirror semaglutide directly